Home>>Signaling Pathways>> DNA Damage/DNA Repair>> CDK>>ON-013100

ON-013100

Catalog No.GC33353

ON-013100, an antineoplastic drug, acts a mitotic inhibitor that could inhibit Cyclin D1 expression.

Products are for research use only. Not for human use. We do not sell to patients.

ON-013100 Chemical Structure

Cas No.: 865783-95-5

Size Price Stock Qty
10mM (in 1mL DMSO)
$109.00
In stock
1mg
$63.00
In stock
5mg
$126.00
In stock
10mg
$195.00
In stock
50mg
$767.00
In stock
100mg
$1,290.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

ON-013100, an antineoplastic drug, acts a mitotic inhibitor that could inhibit Cyclin D1 expression.

ON-013100 induces apoptosis, and has activity against most human cancer cell lines in vitro

[1]. Cho SY, et al. Determination of the glucuronide metabolite of ON 013100, a benzylstyrylsulfone antineoplastic drug, in colon cancer cells using LC/MS/MS. J Pharm Biomed Anal. 2013 Mar 5;75:138-44. [2]. Park IW, et al. Evaluation of novel cell cycle inhibitors in mantle cell lymphoma. Oncogene. 2007 Aug 16;26(38):5635-42. [3]. Neel Jasani, et al. Potent anticancer activity of an orally bioavailable small molecule, ON 013100, and its water soluble derivative, briciclib, a clinical-stage eIF4E-targeted agent. AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA.

Reviews

Review for ON-013100

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ON-013100

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.